Hillsdale Investment Management Inc. Acquires 25,100 Shares of Collegium Pharmaceutical, Inc. $COLL

Hillsdale Investment Management Inc. grew its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 14.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 203,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 25,100 shares during the quarter. Hillsdale Investment Management Inc. owned approximately 0.64% of Collegium Pharmaceutical worth $7,103,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Federated Hermes Inc. increased its holdings in Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares during the period. CWM LLC lifted its holdings in Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 1,153 shares during the period. Hantz Financial Services Inc. boosted its position in Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after acquiring an additional 993 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after acquiring an additional 2,190 shares in the last quarter. Finally, NewEdge Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 304.6% in the 2nd quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after acquiring an additional 2,294 shares during the period.

Insiders Place Their Bets

In other news, EVP Scott Dreyer sold 17,600 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the transaction, the executive vice president directly owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. This represents a 14.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the transaction, the director owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. The trade was a 6.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock opened at $45.00 on Friday. The company has a 50 day moving average price of $46.97 and a 200 day moving average price of $41.71. The firm has a market capitalization of $1.42 billion, a P/E ratio of 27.95 and a beta of 0.64. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $50.79.

Wall Street Analyst Weigh In

COLL has been the subject of a number of analyst reports. Barclays decreased their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research note on Friday, January 9th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Truist Financial set a $58.00 price objective on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Finally, Needham & Company LLC boosted their price objective on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $53.40.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.